Trials / Recruiting
RecruitingNCT06104033
Practice Change With Drug-coated Balloon in Patients With multiVessel Coronary Artery Disease
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Bon-Kwon Koo · Academic / Other
- Sex
- All
- Age
- 19 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, multicenter, open-label, observational study to investigate the impact of using drug-coated balloons (DCBs) in the treatment of coronary artery lesions in patients with multivessel coronary artery disease (MVD), as opposed to the default strategy of using only drug-eluting stents (DES). The investigators aim to assess changes in clinical practice towards a hybrid treatment strategy (DES and DCB) and its effects on clinical outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | drug-coated balloon | For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used. |
| DEVICE | drug-eluting stent | When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines. |
Timeline
- Start date
- 2023-09-18
- Primary completion
- 2025-08-31
- Completion
- 2026-10-31
- First posted
- 2023-10-27
- Last updated
- 2023-10-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06104033. Inclusion in this directory is not an endorsement.